Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

Natasha Amrita Satkunam, MBBS, MSc, Johnny Mahlangu, MD, Christoph Bidlingmaier, MD PD, Dr. MD, Maria Eva Mingot-Castellano, PhD, Meera B. Chitlur, MD, Patrick F. Fogarty, MD, Adam Cuker, MD MS, Maria Elisa Mancuso, MD PhD, Pal André Holme, PhD MD, Julie Grabell, BA, CCRP, Wilma Hopman, MA, Prasad Mathew, MD, Paula D. James, MD

Blood (2016) 128 (22): 875.

https://doi.org/10.1182/blood.V128.22.875.875

Published: 2016

Journal Articles

A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study

Susanne Holzhauer, MD, Christoph Bidlingmaier, MD, Carmen Escuriola Ettingshausen, MD, Susan Halimeh, MD, Alfonso Iorio, MD, Gili Kenet, MD, Brigitte Pautard, MD, Ulrike Nowak-Gottl, MD

Blood (2010) 116 (21): 710.

https://doi.org/10.1182/blood.V116.21.710.710

Published: 2010

Journal Articles

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Alfonso Iorio, MD, Susan Halimeh, MD, Christoph Bidlingmaier, MD, Leonardo R. Brandao, MD, Carmen Escuriola-Ettingshausen, MD, Neil A Goldenberg, MD, PhD, Alessandro Gringeri, MD, MSc, Susanne Holzhauer, MD, Gili Kenet, MD, PhD, Ralf Knoefler, MD, Wolfhart Kreuz, MD, Karin Kurnik, MD, Daniela Manner, MD, Emanuela Marchesini, MD, Maura Marcucci, MD, Elena Santagostino, MD, PhD, Guy Young, MD, Pier Mannuccio Mannucci, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 3154.

https://doi.org/10.1182/blood.V114.22.3154.3154

Published: 2009

Journal Articles

Long-Term Safety and Efficacy Data on Childhood Venous Thrombosis Treated with Enoxaparin: An Open Label Survey of Once-Daily Versus Twice-Daily Administration.

Ulrike Nowak-Gottl, MD, Christine During, MD, Christoph Bidlingmaier, MD, Nick Merkel, MD, Rosemarie Schobess, MD

Blood (2005) 106 (11): 549.

https://doi.org/10.1182/blood.V106.11.549.549

Published: 2005

Journal Articles

Factor V G1691A and Factor II G20210A Mutations and Clinical Expression of Severe Hemophilia A (< 2%) in Children: Impact on Bleeding Episodes and Joint Damage.

Ulrike Nowak-Gottl, MD, Carmen Escuriola, MD, Rosemarie Schobess, MD, Christine Duering, MD, Christoph Bidlingmaier, MD, Hartmut Pollmann, MD, Sylvia Horneff, MD, Karin Kurnik, MD

Blood (2004) 104 (11): 3095.

https://doi.org/10.1182/blood.V104.11.3095.3095

Published: 2004

NARROW

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Long-Term Safety and Efficacy Data on Childhood Venous Thrombosis Treated with Enoxaparin: An Open Label Survey of Once-Daily Versus Twice-Daily Administration.

Factor V G1691A and Factor II G20210A Mutations and Clinical Expression of Severe Hemophilia A (< 2%) in Children: Impact on Bleeding Episodes and Joint Damage.

Email alerts

ASH Publications

American Society of Hematology

Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls

A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Long-Term Safety and Efficacy Data on Childhood Venous Thrombosis Treated with Enoxaparin: An Open Label Survey of Once-Daily Versus Twice-Daily Administration.

Factor V G1691A and Factor II G20210A Mutations and Clinical Expression of Severe Hemophilia A (< 2%) in Children: Impact on Bleeding Episodes and Joint Damage.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only